Who
Craig C. Hopkinson
EVP R&D, Chief Medical Officer
Company insider
Files Form 4 as: EVP R&D, Chief Medical Officer, Alkermes; Director, Albireo Pharma.
In numbers
- Trades disclosed
- 265
- Buys
- 0
- Sells
- 26
- Bought
- $0
- Sold
- $27.9M
- Companies
- 2
- Companies where not an officer
- 1
- First trade
- 16 Feb 2018
- Last trade
- 1 Sep 2026
- Last filed
- 1 Sep 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 1 Sep 2026filed 1 Sep 2026 | ALKS AlkermesPharmaceuticals | SEC FORM 4 Code M | $123K5,000 at $24.59 | filing |
| 1 Sep 2026filed 1 Sep 2026 | ALKS AlkermesPharmaceuticals | SEC FORM 4 Sold | $423K9,000 at $46.99 | filing |
| 1 Sep 2026filed 1 Sep 2026 | ALKS Alkermesoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —5,000 at $0.00 | filing |
| 1 Sep 2026filed 1 Sep 2026 | ALKS Alkermesoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —5,000 at $0.00 | filing |
| 1 Sep 2026filed 1 Sep 2026 | ALKS AlkermesPharmaceuticals | SEC FORM 4 Code M | $123K5,000 at $24.59 | filing |
| 1 Sep 2026filed 1 Sep 2026 | ALKS AlkermesPharmaceuticals | SEC FORM 4 Sold | $423K9,000 at $46.99 | filing |
| 3 Aug 2026filed 3 Aug 2026 | ALKS AlkermesPharmaceuticals | SEC FORM 4 Code M | $2,011104 at $19.34 | filing |
| 3 Aug 2026filed 3 Aug 2026 | ALKS AlkermesPharmaceuticals | SEC FORM 4 Code M | $120K4,896 at $24.59 | filing |
| 3 Aug 2026filed 3 Aug 2026 | ALKS AlkermesPharmaceuticals | SEC FORM 4 Sold | $437K9,000 at $48.58 | filing |
| 3 Aug 2026filed 3 Aug 2026 | ALKS Alkermesoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —104 at $0.00 | filing |
| 3 Aug 2026filed 3 Aug 2026 | ALKS Alkermesoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —4,896 at $0.00 | filing |
| 3 Aug 2026filed 3 Aug 2026 | ALKS Alkermesoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —104 at $0.00 | filing |
| 3 Aug 2026filed 3 Aug 2026 | ALKS Alkermesoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —4,896 at $0.00 | filing |
| 3 Aug 2026filed 3 Aug 2026 | ALKS AlkermesPharmaceuticals | SEC FORM 4 Code M | $2,011104 at $19.34 | filing |
| 3 Aug 2026filed 3 Aug 2026 | ALKS AlkermesPharmaceuticals | SEC FORM 4 Code M | $120K4,896 at $24.59 | filing |
| 3 Aug 2026filed 3 Aug 2026 | ALKS AlkermesPharmaceuticals | SEC FORM 4 Sold | $437K9,000 at $48.58 | filing |
| 1 Jul 2026filed 1 Jul 2026 | ALKS AlkermesPharmaceuticals | SEC FORM 4 Code M | $97K5,000 at $19.34 | filing |
| 1 Jul 2026filed 1 Jul 2026 | ALKS AlkermesPharmaceuticals | SEC FORM 4 Sold | $427K8,300 at $51.46 | filing |
| 1 Jul 2026filed 1 Jul 2026 | ALKS AlkermesPharmaceuticals | SEC FORM 4 Sold | $36K700 at $52.13 | filing |
| 1 Jul 2026filed 1 Jul 2026 | ALKS Alkermesoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —5,000 at $0.00 | filing |
News
Financial Survey: INmune Bio (NASDAQ:INMB) vs. Alkermes (NASDAQ:ALKS)ALKS · themarketsdaily.com · 20 Oct 2026Traders Buy High Volume of Put Options on Alkermes (NASDAQ:ALKS)ALKS · tickerreport.com · 17 Oct 2026Reviewing Alkermes (NASDAQ:ALKS) and uniQure (NASDAQ:QURE)ALKS · tickerreport.com · 13 Oct 2026
0 headlines in the last 90 days name Craig C. Hopkinson; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.